SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-044197
Filing Date
2019-02-19
Accepted
2019-02-19 16:00:34
Documents
6
Period of Report
2019-02-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d686689d8k.htm 8-K 29887
2 EX-10.1 d686689dex101.htm EX-10.1 725494
3 EX-10.2 d686689dex102.htm EX-10.2 12531
4 EX-99.1 d686689dex991.htm EX-99.1 14662
5 GRAPHIC g686689crg.jpg GRAPHIC 4246
6 GRAPHIC g686689g0216094604153.jpg GRAPHIC 3399
  Complete submission text file 0001193125-19-044197.txt   794961
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 19614921
SIC: 3826 Laboratory Analytical Instruments